Nomoto, H.; Takahashi, Y.; Takano, Y.; Yokoyama, H.; Tsuchida, K.; Nagai, S.; Miya, A.; Kameda, H.; Cho, K.Y.; Nakamura, A.;
et al. Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis. Pharmaceutics 2023, 15, 2163.
https://doi.org/10.3390/pharmaceutics15082163
AMA Style
Nomoto H, Takahashi Y, Takano Y, Yokoyama H, Tsuchida K, Nagai S, Miya A, Kameda H, Cho KY, Nakamura A,
et al. Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis. Pharmaceutics. 2023; 15(8):2163.
https://doi.org/10.3390/pharmaceutics15082163
Chicago/Turabian Style
Nomoto, Hiroshi, Yuka Takahashi, Yoshinari Takano, Hiroki Yokoyama, Kazuhisa Tsuchida, So Nagai, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Akinobu Nakamura,
and et al. 2023. "Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis" Pharmaceutics 15, no. 8: 2163.
https://doi.org/10.3390/pharmaceutics15082163
APA Style
Nomoto, H., Takahashi, Y., Takano, Y., Yokoyama, H., Tsuchida, K., Nagai, S., Miya, A., Kameda, H., Cho, K. Y., Nakamura, A., & Atsumi, T.
(2023). Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis. Pharmaceutics, 15(8), 2163.
https://doi.org/10.3390/pharmaceutics15082163